1. Home
  2. DVAX vs GIII Comparison

DVAX vs GIII Comparison

Compare DVAX & GIII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DVAX
  • GIII
  • Stock Information
  • Founded
  • DVAX 1996
  • GIII 1956
  • Country
  • DVAX United States
  • GIII United States
  • Employees
  • DVAX N/A
  • GIII N/A
  • Industry
  • DVAX Biotechnology: Pharmaceutical Preparations
  • GIII Apparel
  • Sector
  • DVAX Health Care
  • GIII Consumer Discretionary
  • Exchange
  • DVAX Nasdaq
  • GIII Nasdaq
  • Market Cap
  • DVAX 1.2B
  • GIII 1.2B
  • IPO Year
  • DVAX 2004
  • GIII 1989
  • Fundamental
  • Price
  • DVAX $10.44
  • GIII $28.18
  • Analyst Decision
  • DVAX Buy
  • GIII Hold
  • Analyst Count
  • DVAX 4
  • GIII 5
  • Target Price
  • DVAX $26.50
  • GIII $28.40
  • AVG Volume (30 Days)
  • DVAX 1.3M
  • GIII 361.4K
  • Earning Date
  • DVAX 11-05-2025
  • GIII 12-09-2025
  • Dividend Yield
  • DVAX N/A
  • GIII N/A
  • EPS Growth
  • DVAX N/A
  • GIII 0.24
  • EPS
  • DVAX N/A
  • GIII 4.02
  • Revenue
  • DVAX $316,268,000.00
  • GIII $3,123,169,000.00
  • Revenue This Year
  • DVAX $23.23
  • GIII N/A
  • Revenue Next Year
  • DVAX $16.57
  • GIII N/A
  • P/E Ratio
  • DVAX N/A
  • GIII $7.06
  • Revenue Growth
  • DVAX 26.66
  • GIII 1.19
  • 52 Week Low
  • DVAX $9.20
  • GIII $20.33
  • 52 Week High
  • DVAX $14.63
  • GIII $36.18
  • Technical
  • Relative Strength Index (RSI)
  • DVAX 58.99
  • GIII 59.61
  • Support Level
  • DVAX $10.03
  • GIII $27.97
  • Resistance Level
  • DVAX $10.59
  • GIII $28.92
  • Average True Range (ATR)
  • DVAX 0.22
  • GIII 0.81
  • MACD
  • DVAX 0.06
  • GIII 0.13
  • Stochastic Oscillator
  • DVAX 81.25
  • GIII 81.84

About DVAX Dynavax Technologies Corporation

Dynavax Technologies Corp is a biopharmaceutical company. The company focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor stimulation. Its current product candidates are being investigated for use in multiple cancer indications as a vaccine for the prevention of HEPLISAV-B (Hepatitis B Vaccine (Recombinant), Adjuvanted), operates in the business segment of discovery, development, and commercialization of novel vaccines. Its Toll-like Receptor Immune Modulation Platform technology plays a vital role in innate immunity and subsequent adaptive immunity. The company generates the vast majority of its revenue from the sale of its CpG 1018 product and HEPLISAV-B.

About GIII G-III Apparel Group LTD.

G-III Apparel Group Ltd is a textile company. It makes a wide range of apparel, footwear, and accessories that it sells under its own brands, licensed brands, and private-label brands. G-III has a substantial portfolio for licensed and proprietary brands, anchored by five global power brands: DKNY, Donna Karan, Calvin Klein, Tommy Hilfiger, and Karl Lagerfeld. The company has two reportable operations: Wholesale Operations and Retail Operations. The Wholesale operations segment includes sales of products under brands licensed by from third parties, as well as sales of products under its own brands and private label brands. The retail operations segment consists of Wilsons Leather, G.H. Bass, and DKNY retail stores. It derives majority of its revenues from Wholesale operations.

Share on Social Networks: